BioXcel Therapeutics, Inc. Earnings Per Share, Basic and Diluted
BioXcel Therapeutics, Inc. (BTAI) reported Earnings Per Share, Basic and Diluted of -$0.96 per share for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-11-10
- BioXcel Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.96.
- BioXcel Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.11.
- BioXcel Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$1.08.
- BioXcel Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.86.
- BioXcel Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$3.79.
- BioXcel Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$2.02.
- BioXcel Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2018 was -$1.32.
- BioXcel Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2017 was -$0.47.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$0.96 10-Q · filed 2021-11-10 | -$2.06 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$3.13 10-Q · filed 2021-11-10 | -$4.00 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$1.11 10-Q · filed 2021-08-10 | -$2.18 10-Q · filed 2021-08-10 | -$3.05 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$4.12 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-03-31 | -$1.08 10-Q · filed 2021-05-10 | -$1.94 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$3.01 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$4.06 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2020-12-31 | -$0.86 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$1.93 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$2.98 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$3.79 10-K · filed 2021-03-12 |
| 2020-09-30 | -$1.07 10-Q · filed 2021-11-10 | -$2.13 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$2.94 10-Q · filed 2021-11-10 | -$3.45 derived: net income ÷ weighted average shares · filed 2021-11-10 |
| 2020-06-30 | -$1.06 10-Q · filed 2021-08-10 | -$1.85 10-Q · filed 2021-08-10 | -$2.33 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$2.93 derived: net income ÷ weighted average shares · filed 2021-11-10 |
| 2020-03-31 | -$0.79 10-Q · filed 2021-05-10 | -$1.25 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$1.83 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$2.38 derived: net income ÷ weighted average shares · filed 2021-11-10 |
| 2019-12-31 | -$0.46 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$1.02 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$1.56 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$2.02 10-K · filed 2021-03-12 |
| 2019-09-30 | -$0.57 10-Q · filed 2020-11-12 | -$1.11 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$1.57 10-Q · filed 2020-11-12 | -$2.03 derived: net income ÷ weighted average shares · filed 2020-11-12 |
| 2019-06-30 | -$0.54 10-Q · filed 2020-08-14 | -$1.00 10-Q · filed 2020-08-14 | -$1.45 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$1.77 derived: net income ÷ weighted average shares · filed 2020-11-12 |
| 2019-03-31 | -$0.46 10-Q · filed 2020-05-12 | -$0.91 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$1.23 derived: net income ÷ weighted average shares · filed 2020-11-12 | -$1.42 derived: net income ÷ weighted average shares · filed 2020-11-12 |
| 2018-12-31 | -$0.45 derived: net income ÷ weighted average shares · filed 2020-03-09 | -$0.77 derived: net income ÷ weighted average shares · filed 2020-03-09 | -$0.96 derived: net income ÷ weighted average shares · filed 2020-03-09 | -$1.32 10-K · filed 2020-03-09 |
| 2018-09-30 | -$0.31 10-Q · filed 2019-11-14 | -$0.51 derived: net income ÷ weighted average shares · filed 2019-11-14 | -$0.86 10-Q · filed 2019-11-14 | -$1.11 derived: net income ÷ weighted average shares · filed 2019-11-14 |
| 2018-06-30 | -$0.19 10-Q · filed 2019-08-06 | -$0.54 10-Q · filed 2019-08-06 | -$0.79 derived: net income ÷ weighted average shares · filed 2019-11-14 | -$0.92 derived: net income ÷ weighted average shares · filed 2019-11-14 |
| 2018-03-31 | -$0.37 10-Q · filed 2019-05-07 | -$0.63 derived: net income ÷ weighted average shares · filed 2019-11-14 | -$0.74 derived: net income ÷ weighted average shares · filed 2019-11-14 | -$0.81 derived: net income ÷ weighted average shares · filed 2019-11-14 |
| 2017-12-31 | -$0.25 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$0.35 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$0.41 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$0.47 10-K · filed 2019-03-12 |
| 2017-09-30 | -$0.10 10-Q · filed 2018-11-09 | -$0.16 derived: net income ÷ weighted average shares · filed 2018-11-09 | -$0.21 10-Q · filed 2018-11-09 | |
| 2017-06-30 | -$0.06 10-Q · filed 2018-08-08 | -$0.12 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | -$0.06 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |